{
    "ticker": "RARE",
    "name": "Ultragenyx Pharmaceutical Inc.",
    "description": "Ultragenyx Pharmaceutical Inc. is a biotechnology company dedicated to the development of innovative products for the treatment of rare and ultra-rare genetic diseases. Founded in 2010, Ultragenyx focuses on addressing unmet medical needs in the field of rare diseases by leveraging cutting-edge science and technology. The company's portfolio includes a range of investigational therapies aimed at treating conditions such as X-linked hypophosphatemia (XLH) and other genetic disorders. Ultragenyx's flagship product, Crysvita (burosumab), has been approved for the treatment of XLH, marking a significant milestone in the company\u2019s mission to improve the quality of life for patients with rare diseases. The company is committed to advancing the science behind gene therapy and enzyme replacement therapy, with several other candidates in clinical development. Ultragenyx actively collaborates with academic institutions and other biopharmaceutical companies to further its research and development initiatives. With a strong focus on patient advocacy, Ultragenyx engages with the rare disease community to better understand their challenges and needs, ensuring that its research aligns with the real-world experiences of patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Novato, California, USA",
    "founded": "2010",
    "website": "https://www.ultragenyx.com",
    "ceo": "Emil D. Kakkis, M.D., Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/Ultragenyx",
        "linkedin": "https://www.linkedin.com/company/ultragenyx-pharmaceuticals"
    },
    "investor_relations": "https://investors.ultragenyx.com",
    "key_executives": [
        {
            "name": "Emil D. Kakkis, M.D., Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Amit S. Munshi",
            "position": "President"
        },
        {
            "name": "Sharon M. Gentry",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Crysvita (burosumab)",
                "UX007",
                "UX143"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ultragenyx Pharmaceutical Inc. | Innovative Treatments for Rare Diseases",
        "meta_description": "Ultragenyx Pharmaceutical Inc. is at the forefront of developing therapies for rare and ultra-rare genetic diseases. Learn about their innovative approach and current treatments.",
        "keywords": [
            "Ultragenyx",
            "Rare Diseases",
            "Biotechnology",
            "Pharmaceuticals",
            "Crysvita",
            "Gene Therapy"
        ]
    },
    "faq": [
        {
            "question": "What does Ultragenyx specialize in?",
            "answer": "Ultragenyx specializes in developing therapies for rare and ultra-rare genetic diseases."
        },
        {
            "question": "What is Crysvita?",
            "answer": "Crysvita is an FDA-approved treatment for X-linked hypophosphatemia (XLH)."
        },
        {
            "question": "Where is Ultragenyx headquartered?",
            "answer": "Ultragenyx is headquartered in Novato, California, USA."
        },
        {
            "question": "When was Ultragenyx founded?",
            "answer": "Ultragenyx was founded in 2010."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "SNY",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}